FDA DEVICE FACTS
Magma System
Formatk Systems , Ltd.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Magma System is indicated for use in surgical, aesthetic applications in the medical specialties of general and plastic surgery, and dermatology. The Magma System has connection capability with the following available treatment handpieces, for multi-application treatment options . All handpieces are designed for aesthetic and dermatological skin procedure applications, as follows:
1. The Magma System with ALD/LLD Laser Handpiece is in dicated for hair removal, permanent hair reduction* in skin types I-VI and fo r the treatment of Pseudofolliculitis Barbae (PFB).
2. The Magma System with Nd:YAG Laser Handpiece (ND) with a wavelength of 1064 nm (Multi-Spot Nd:YAG) is indicated for:
• The coagulation and hemostasis of vascular lesion s and soft tissue, including the treatment and clearance of superficial and deep tel angiectasias (venulectasias) and reticular veins (0.1 - 4.0 mm. diameter) of the leg.
• The removal of unwanted hair from all skin types, and to effect stable long term, or permanent hair reduction* in skin types I-V through selective targeting of melanin in hair follicles.
• The non-ablative treatment of facial wrinkles.
3. The Magma System with the Intense Pulsed Light ( IPL) Handpieces (10 different Applicators) with a spectrum of 430-1100nm is indicated for: HR*, F-HR*, B-HR* Applicators (650-1100nm):
• Removal of unwanted hair from all skin types, and to effect stable long term, or permanent hair reduction* in skin types I-V through selective targeting of melanin in hair follicles. HR, F-HR, B-HR Applicators (590-1100nm):
• Removal of unwanted hair from skin types I-IV, an d to effect stable long term, or permanent hair reduction* in skin types I-IV throug h selective targeting of melanin in hair follicles. SR, F-SR, B-SR Applicators (530-1100nm):
• Benign epidermal lesions, including dyschromia, h yperpigmentation, ephelides (freckles)
• Cutaneous lesions, including striae.
• Benign cutaneous vascular lesions, including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, erythema o f rosacea, angiomas and spider angiomas, poikiloderma of Civatte, leg veins and venous malformations. F-AC Applicator (430-1100nm):
• Mild to moderate inflammatory Acne (Acne vulgaris). *Note Permanent hair reduction is defined as the long-ter m, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 month s after the completion of a treatment regime.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。